Article Text

Download PDFPDF

AB0098 Effects of tofacitinib in early arthritis bone loss
  1. B Vidal1,
  2. R Cascão1,
  3. M Finnilä2,3,
  4. I Lopes1,
  5. S Saarakkala2,4,5,
  6. P Zioupos6,
  7. H Canhão7,
  8. J Fonseca1,8
  1. 1Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
  2. 2Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulo
  3. 3Department of Applied Physics, University of Eastern Finland, Kuopio
  4. 4Medical Research Center, University of Oulu
  5. 5Department of Diagnostic Radiology, Oulu University Hospital, Oulo, Finland
  6. 6Biomechanics Labs, Cranfield Forensic Institute, Cranfield University, Swindon, United Kingdom
  7. 7EpiDoC Unit, CEDOC, NOVA Medical School, NOVA University
  8. 8Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisboa, Portugal


Background Rheumatoid arthritis (RA) causes immune mediated local and systemic bone damage.

Objectives The main goal of this work was to analyze, how treatment intervention with tofacitinib prevents the early disturbances on bone structure and mechanics in adjuvant induced arthritis rat model. This is the first study to access the impact of tofacitinib on the systemic bone effects of inflammation.

Methods Fifty Wistar adjuvant-induced arthritis (AIA) rats were randomly housed in experimental groups, as follows: non-arthritic healthy group (N=20), arthritic non-treated (N=20) and 10 animals under tofacitinib treatment. Rats were monitored during 22 days after disease induction for the inflammatory score, ankle perimeter and body weight. Healthy non-arthritic rats were used as controls for comparison. After 22 days of disease progression rats were sacrificed and bone samples were collected for histology, micro-CT, 3-point bending and nanoindentation analysis. Blood samples were also collected for bone turnover markers and systemic cytokine quantification.

Results At tissue level, measured by nanoindentation, tofacitinib increased bone cortical and trabecular hardness. However, micro-CT and 3-point bending tests revealed that tofacitinib did not revert the effects of arthritis on cortical and trabecular bone structure and on mechanical properties.

Conclusions Possible reasons for these observations might be related with the mechanism of action of tofacitinib, which leads to direct interactions with bone metabolism, and/or with kinetics of its bone effects that might need longer exposure.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.